John Fung to Anti-Bacterial Agents
This is a "connection" page, showing publications John Fung has written about Anti-Bacterial Agents.
Connection Strength
0.589
-
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc. 1991 Feb; 23(1 Pt 1):14-21.
Score: 0.067
-
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc. 1990 Feb; 22(1):52-6.
Score: 0.062
-
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc. 1990 Feb; 22(1):6-12.
Score: 0.062
-
Overview of FK506 in transplantation. Clin Transpl. 1990; 115-21.
Score: 0.062
-
Infectious complications after human small bowel transplantation. Transplant Proc. 1992 Jun; 24(3):1249-50.
Score: 0.018
-
FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery. 1991 Aug; 110(2):357-63; discussion 363-4.
Score: 0.017
-
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991 Jul; 52(1):71-7.
Score: 0.017
-
Effects of in vivo treatment with FK506 on natural killer cells in rats. Transplantation. 1991 Apr; 51(4):913-5.
Score: 0.017
-
Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. Transplant Proc. 1991 Feb; 23(1 Pt 2):1108-10.
Score: 0.017
-
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc. 1991 Feb; 23(1 Pt 2):1397-402.
Score: 0.017
-
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc. 1991 Feb; 23(1 Pt 2):914-9.
Score: 0.017
-
Use of FK 506 in pediatric patients. Transplant Proc. 1991 Feb; 23(1 Pt 2):924-7.
Score: 0.017
-
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg. 1990 Sep; 212(3):295-305; discussion 306-7.
Score: 0.016
-
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation. 1990 Aug; 50(2):186-9.
Score: 0.016
-
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet. 1990 Mar 17; 335(8690):674.
Score: 0.016
-
Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):106-9.
Score: 0.016
-
FK 506 dosage in human organ transplantation. Transplant Proc. 1990 Feb; 22(1):23-4.
Score: 0.016
-
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):25-34.
Score: 0.016
-
The side effects of FK 506 in humans. Transplant Proc. 1990 Feb; 22(1):35-6.
Score: 0.016
-
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc. 1990 Feb; 22(1):41-3.
Score: 0.016
-
Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc. 1990 Feb; 22(1):44-6.
Score: 0.016
-
Assay of FK 506 in plasma. Transplant Proc. 1990 Feb; 22(1):50-1.
Score: 0.016
-
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc. 1990 Feb; 22(1):57-9.
Score: 0.016
-
Studies of the hepatotrophic qualities of FK 506 and CyA. Transplant Proc. 1990 Feb; 22(1):93-5.
Score: 0.016
-
Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg. 1996 Jan; 223(1):70-6.
Score: 0.006
-
Liver transplantation under cyclosporine: a decade of experience. Transplant Proc. 1991 Feb; 23(1 Pt 2):1393-6.
Score: 0.004